Sign In
Buy HAE
$65.88
-0.490 (-0.738%)
At Close: Jun 03, 2026
Zimmer Biomet (ZBH) Surpasses Q2 Earnings and Revenue Estimates
11:55am, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Zimmer (ZBH) delivered earnings and revenue surprises of 11.66% and 3.31%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Hospital Arm Thrives, Gross Margin Rises
02:29pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Strong procedure recovery in the hospital business, the resilience of blood donors in blood centers and rollouts of Persona technology and NexSys aid Haemonetics (HAE).
Here's Why You Should Retain Haemonetics (HAE) Stock For Now
03:14pm, Friday, 08'th Jul 2022 Zacks Investment Research
Investors are optimistic about Haemonetics' (HAE) robust performances across the Hospital and Plasma businesses.
Here's Why You Should Retain Haemonetics (HAE) Stock For Now
12:25pm, Friday, 08'th Jul 2022
Investors are optimistic about Haemonetics' (HAE) robust performances across the Hospital and Plasma businesses.
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2023 Results: August 10, 2022
04:05pm, Thursday, 07'th Jul 2022
BOSTON , July 7, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2023 financial results at 6:00 am EDT on Wednesday, Au
Haemonetics: Upside Case Hinges On Blood Plasma Collection Market
08:50am, Saturday, 11'th Jun 2022
The debate on Haemonetics largely rests on growth in the blood plasma market. More than 35% of revenues are exposed to this segment, and growth of the market has been volatile in recent years.
Haemonetics (HAE) Up 28.2% Since Last Earnings Report: Can It Continue?
03:30pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics (HAE) Up 28.2% Since Last Earnings Report: Can It Continue?
12:47pm, Thursday, 09'th Jun 2022
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?
Haemonetics (HAE) Gains on Procedure Recovery Amid Cost Woes
01:59pm, Friday, 27'th May 2022 Zacks Investment Research
A strong procedure recovery in the hospital business, the resilience of blood donors in blood centers, and rollouts of Persona technology and NexSys aid Haemonetics (HAE).
Here's Why Investors Should Retain Haemonetics (HAE) For Now
03:45pm, Monday, 23'rd May 2022 Zacks Investment Research
Investors are optimistic about Haemonetics's (HAE) better-than-expected results and robust segmental performance.
Here's Why Investors Should Retain Haemonetics (HAE) For Now
12:48pm, Monday, 23'rd May 2022
Investors are optimistic about Haemonetics's (HAE) better-than-expected results and robust segmental performance.
Haemonetics (HAE) Q4 Earnings Top Estimates, Gross Margin Up
03:12pm, Wednesday, 11'th May 2022 Zacks Investment Research
Robust performance by Plasma and Hospital businesses drove Haemonetics' (HAE) revenues in the fiscal fourth quarter.
Haemonetics (HAE) Q4 Earnings Top Estimates, Gross Margin Up
12:48pm, Wednesday, 11'th May 2022
Robust performance by Plasma and Hospital businesses drove Haemonetics' (HAE) revenues in the fiscal fourth quarter.
Haemonetics Corporation (HAE) CEO Chris Simon on Q4 2022 Results - Earnings Call Transcript
03:58pm, Tuesday, 10'th May 2022
Haemonetics Corporation (NYSE:HAE ) Q4 2022 Results Conference Call May 10, 2022 8:00 AM ET Company Participants Olga Guyette - Director, IR and Treasury Chris Simon - CEO James D'Arecca - CFO Confere
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
11:35am, Tuesday, 10'th May 2022 Zacks Investment Research
Haemonetics (HAE) delivered earnings and revenue surprises of 8.33% and 2.56%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
